FDA warned Maximus Health that its website makes false or misleading claims about compounded semaglutide and tirzepatide.
What happened
During a May 2026 review of Maximus’s website, FDA found that the site offered compounded semaglutide and tirzepatide products and made claims such as “Clinically studied ingredients” and “Proven to lose weight effectively.” FDA also said the site described the products’ sources as “FDA approved pharmacies.” FDA cited these statements as false or misleading because compounded drug products and compounding pharmacies or outsourcing facilities are not FDA-approved.
What FDA found
The website’s claims that the compounded semaglutide and tirzepatide products have “clinically studied ingredients” and are “proven to lose weight effectively” falsely suggest FDA approval or evaluation.
FD&C Act §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]The website says the products are sourced from “FDA approved pharmacies,” which falsely implies compounding pharmacies or outsourcing facilities are FDA-approved or licensed.
FD&C Act §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]FDA said these misbranded products were introduced or delivered for introduction into interstate commerce.
FD&C Act § 301(a) [21 U.S.C. § 331(a)]
What FDA wants
FDA asks Maximus to investigate root causes and take corrective and preventive actions, and to send a written response to FDA’s Office of Compounding Quality and Compliance within 15 business days. The response should identify the entities that produce the compounded products, include a sample of labeling, and address the false or misleading website claims.
Who should pay attention
- telehealth companies selling compounded semaglutide or tirzepatide
- compounding pharmacies and outsourcing facilities named in marketing
- marketing and compliance teams for online pharmacy websites
This is a summary. Read the original letter on fda.gov.